CD163: A Highly Specific Marker for Myeloid Leukemia Cutis
PW Harms, L Ma. University of Michigan Health Systems, Ann Arbor, MI
Background: Recognition of myeloid leukemia cutis (LC) is clinically important. However, currently used immunohistochemical markers can be insufficiently sensitive and/or specific for definitive diagnosis. CD163, a haptoglobin-hemoglobin scavenger receptor, has been shown to be largely restricted to the monocyte/histiocyte lineage. We investigated the utility of CD163 in the diagnosis of myeloid LC with a monocytic component.
Design: A total of 34 cases, including 18 cases of myelomonocytic or monocytic LC (acute myeloid leukemia, M4 or M5), 10 cases of myeloid LC without monocytic component, and 6 cases of T- or B-cell acute lymphoblastic leukemia/lymphoma, were stained for CD163.
Results: We observed CD163 expression in 8 of 18 (44%) of myelomonocytic or monocytic LC and 1 of 10 (10%) of other myeloid LC. CD163 was not expressed in any of the acute lymphoblastic leukemia/lymphoma cases (0/6). Results are summarized in Table 1.
|AML, other than M4-5||1/10 (10%)|
|AML, all||9/28 (32%)|